• Prostate and other male cancers

Firmagon Generic Name & Formulations

General Description

Degarelix 80mg/vial, 120mg/vial; pwd for SC inj after reconstitution.

Pharmacological Class

GnRH antagonist.

How Supplied

Treatment Initiation pack (120mg/vial)—2 (w. supplies); Treatment Maintenance pack (80mg/vial)—1 (w. supplies)

Firmagon Indications


Advanced prostate cancer.

Firmagon Dosage and Administration


Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.


Not established.

Firmagon Contraindications

Not Applicable

Firmagon Boxed Warnings

Not Applicable

Firmagon Warnings/Precautions


Congenital long QT syndrome. CHF. Correct electrolyte abnormalities. Monitor electrolytes and ECG periodically. Monitor serum PSA. Discontinue if serious hypersensitivity reaction occurs; do not rechallenge. Moderate or severe renal impairment (CrCl <50mL/min). Severe hepatic impairment. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.

Firmagon Pharmacokinetics

See Literature

Firmagon Interactions


Caution with concomitant drugs known to prolong the QT interval.

Firmagon Adverse Reactions

Adverse Reactions

Inj site reactions (eg, pain, erythema, swelling, induration), hot flashes, increased weight, fatigue, increased transaminases, increased gamma-glutamyltransferase; QT prolongation.

Firmagon Clinical Trials

See Literature

Firmagon Note

Not Applicable

Firmagon Patient Counseling

See Literature